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The  acknowledgement  that  metabolic  reprogramming  is a central  feature  of cancer  has  generated  high
expectations  for  major  advances  in  both  diagnosis  and  treatment  of  malignancies  through  addressing
metabolism.  These  have  so  far only  been  partially  fulﬁlled,  with  only  a few  clinical  applications.  How-
ever,  numerous  diagnostic  and therapeutic  compounds  are  currently  being  evaluated  in either  clinical
trials  or  pre-clinical  models  and  new  discoveries  of  alterations  in metabolic  genes  indicate  future  pro-iomarkers
ancer metabolism
ancer therapeutics
linical trials
maging
gnostic  or  other  applicable  relevance.  Altogether,  these  metabolic  approaches  now  stand  alongside  other
available  measures  providing  hopes  for the  prospects  of  metabolomics  in the  clinic.  Here  we present
a  comprehensive  overview  of  both  ongoing  and  emerging  clinical,  pre-clinical  and  technical  strategies
for  exploiting  unique  tumour  metabolic  traits,  highlighting  the  current  promises  and  anticipations  of
research  in  the  ﬁeld.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
A metabolic rewiring, whereby cells ﬂexibly use alternative
etabolic pathways depending on their needs, is now believed
o occur in virtually all types of cancer [1]. The addiction of
alignant cells to glucose was ﬁrst discovered in the early 20th
entury [2], and by now, it is known that the ability of can-
er cells to adapt their metabolism in response to challenging
onditions is a much more general phenomenon than previously
hought. Besides glucose, a major role for glutamine as a metabolic
ubstrate has been highlighted in several malignancies [3,4]. The
mportance of non-essential amino acids like serine, proline and
rginine has also been appreciated recently [5–8]. The ongo-
ng accumulation of knowledge raises hopes that understanding
umour metabolism will provide new ways for predicting, diag-
osing, and even treating cancers. However, to what extent has
ur current understanding in the ﬁeld actually been converted into
linical applications?
Targeting tumour-speciﬁc metabolism in patients, while avoid-
ng dose-limiting systemic toxicity, has so far proved a difﬁcult
ask since many metabolic alterations in cancers are quantitative
ifferences in ﬂux through physiological pathways. More promis-
ng targets may  be found in tumours carrying mutations in genes
ncoding metabolic enzymes, where cancer cell speciﬁc products,
ermed “oncometabolites”, may  reach high levels. Examples are 2-
ydroxyglutarate (2HG), produced due to oncogenic mutations in
socitrate dehydrogenase (IDH), or succinate and fumarate, which
re elevated due to the loss of function of succinate dehydroge-
ase (SDH) or fumarate hydratase (FH), respectively [9,10]. These
ancers are more likely to contain profound adaptations to their
enetically imposed metabolic state, and so demonstrate cancer-
peciﬁc addictions and vulnerabilities.
Distinct metabolic proﬁles have already been described for cer-
ain tumours [11–13], several metabolic biomarkers are used in
he clinic, and a number of drugs targeting metabolic pathways
re employed to treat cancers. Still, many metabolism-speciﬁc can-
er diagnostics and treatments are at a pre-clinical stage only, and
outine targeting of metabolism as a general therapeutic strategy
emains challenging. In this review, we present a comprehensive
ummary of the current clinical applications of metabolomics, of
reas in advanced stages of development and of those that remain . . . . . . . . . . .  . . .  . . . . .  . . . . .  . . . . .  . . .  .  . . . .  . . .  . . .  . .  . .  .  . . . .  . . .  .  .  .  . . . .  .  . . . . .  . . . . .  . . . 61
putative thus providing the reader with a timely overview of the
bench-to-bedside studies of tumour metabolomes.
2. Currently approved clinical applications
In this section we review conﬁrmed metabolic approaches
ﬁrmly established as strategies for clinical management of cancer
patients.
2.1. Anti-metabolites
Compounds that inhibit cell proliferation through interference
with RNA and DNA synthesis have been in use as anti-neoplastic
agents for many decades. Known under the broad (and confusing)
name “anti-metabolites” – the term refers stricto sensu to drugs
that block nucleotide biosynthesis, affecting RNA/DNA metabolism
– these drugs can be divided into several subgroups: anti-purines
(e.g. 6-thioguanine), anti-pyrimidines (e.g. 5-ﬂuorouracil, aka 5FU),
nucleoside analogues (e.g. gemcitabine and cytarabine) and anti-
folates (e.g. methotrexate) [14].
One of the most widely used “anti-metabolites” is 5FU, a syn-
thetic analogue of the nucleic acid uracil, containing a ﬂuoride
atom at the ﬁfth carbon position. 5FU is converted by thymidylate
synthase into two active metabolites: 5-ﬂuoro-2′-deoxyuridine
monophosphate (Fd-UMP) and 5-ﬂuorouridine triphosphate (F-
UTP). However, the ﬂuoride atom prevents the addition of a
methyl group at carbon 5, thereby preventing further reactions.
Thus, Fd-UMP and F-UTP inhibit thymidylate synthase activity via
product inhibition, causing lack of the nucleotide deoxythymidine
monophosphate. Consequently, DNA replication and cell prolifer-
ation are arrested. In addition, F-UTP is incorporated into RNA as
a “false building block”, impairing the synthesis and maturation
of all the classes of RNA [15,16]. Due to its broad cytotoxic activity,
5FU and, increasingly, its orally available pro-drug capecitabine, are
indicated for several malignancies including most gastrointestinal
cancers [17,18]. Actual nucleoside analogues such as gemcitabine
and cytarabine are routinely used alone or in combination with
other drugs against a wide range of cancers. They are processed
within the cell and incorporated into DNA thus impeding replica-
tion and proliferation [14].
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Fig. 1. Approaches to analytical metabolomics in cancer patients. Pharmacological and radiological anti-cancer therapies as well as intentional and accidental changes
in  dietary intake constitute rather general modiﬁcations of tumour cell metabolism and have to be taken into account for analytical considerations. In order to track
their  metabolic fates (by liquid or gas chromatography–coupled mass spectrometry) in excised malignant as well as non-cancerous tissues or body ﬂuids, speciﬁc stable
isotope-labelled metabolic precursors can be administered to a patient. Body ﬂuids that can be repeatedly sampled by non- or minimally-invasive procedures, and therefore
enable dynamic monitoring over time, reﬂect an “integrative” picture of tumour-derived alterations of systemic metabolism. In contrast, comparative analyses of resected
cancerous and non-malignant tissues, either immediately prepared for metabolomic processing or monitored as ex vivo cultures may  provide direct insights into tumour-
speciﬁc metabolic changes. Modern imaging techniques including positron emission tomography (PET) and nuclear magnetic resonance detection based on radioactively-
labelled  (PET) or 13C-hyperpolarised (MRS imaging) metabolites are increasingly employed to functionally monitor malignant lesions and therapeutic responses. FDG,
ﬂ
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Another class of widely used anti-metabolites comprises the
nti-folates (e.g. methotrexate), antagonists of folic acid (vitamin
9) metabolism. In the 1940s, a folate antagonist (aminopterin)
as found effective against acute lymphoblastic leukaemia (ALL)
fter the initial observation that low folate diets lowered the white
lood cell counts of leukaemia patients [19]. With less toxic side
ffects and high efﬁciency, methotrexate has become a powerful
tandard treatment for ALL, lymphoma and more. Normally, folate
s reduced by dihydrofolate reductase (DHFR) into dihydrofolate
nd then further into tetrahydrofolate (THF), a methyl group donor
or many enzymes including thymidylate synthase. Anti-folates
ind DHFR, diminishing the production of bases for DNA or RNA
ynthesis [14]. Importantly, methotrexate toxicity to normal tis-
ues is prevented by administrating folinic acid starting 24 up to
2 h after methotrexate dosing [20].
.2. Metabolic tracers for cancer detection
Some cancer-speciﬁc metabolic alterations are exploited
s powerful diagnostic tools. By taking advantage of their
nhanced glucose uptake, malignant glycolytic tissues are detected
y administrating the radioactively labelled glucose analogue
8ﬂuoro-deoxyglucose (FDG) and measuring site-speciﬁc radioac-
ive emission by positron emission tomography (PET). Developed
ack in 1978, FDG can be taken up by glycolytic cells and phospho-
ylated by hexokinase, but as it lacks a 2′ hydroxyl group needed forsubsequent metabolism, it is trapped in the cells in its phosphory-
lated form [21]. FDG-PET detection is now clinically used for various
lymphomas and is being evaluated in a variety of other cancer types
[22]. However, the inherent limitations of this method (costs, short
half-life and “false positive” signals due to inﬂammatory processes)
prevent across the board application [23].
2.3. Interfering with metabolite availability
Apart from glucose, tumours may  require other nutrients
more speciﬁcally, and different cancer types may have distinct
metabolite requirements. For instance, ALL cells were found to
be dependent on exogenous supply (“auxotrophic”) for both
asparagine and glutamine [24], leading to the use of asparaginases
as part of multimodal treatment approaches [25]. By hydrolysing
asparagine to aspartate, asparaginases deplete serum asparagine
(as well as glutamine due to cross reactivity [26]), thus sensitising
the weakened ALL cells to conventional chemotherapy. To date, the
use of asparaginase for ALL remains the only case of direct transla-
tion of “pure scientiﬁc metabolic knowledge” to potent, approved
cancer treatment.3. Emerging clinical metabolic technologies
This section describes advanced new investigational technolo-
gies, which are in the clinical application stage (illustrated in Fig. 1).
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.1. Broadening the array of cancer tracers
A new generation of metabolic PET-tracers, beyond FDG, is
merging and is currently being evaluated in clinical trials. Addi-
ionally, we  are seeing rapid development of hyperpolarised
3C-labelled metabolic tracers for magnetic resonance spec-
roscopy (MRS) imaging. Table 1 summarises current clinical trials
nvestigating metabolism-based approaches to cancer imaging.
.1.1. 11C-Acetate
Systemically available acetate is taken up by cells to produce
cetyl-CoA, which follows either a catabolic route (feeding the TCA
ycle), or an anabolic pathway (for fatty acid and, to a lesser extent,
mino acid synthesis [27]). Indeed, many cancer types show high
xpression of fatty acid synthase (FAS) [28]. Yoshimoto et al. pub-
ished the ﬁrst study highlighting the metabolic role of acetate in
alignant tumours. They showed acetate-derived 14C accumula-
ion in lipid membranes as well as a correlation between acetate
onsumption and the growth rate of cancer cell lines [27]. The
etabolic importance of acetate was further emphasised in mul-
iple malignancies [29–31]. Several studies tracing 11C-labelled
cetate have been published with promising results (e.g. [32]).
.1.2. Tracing one carbon metabolism: choline and methionine
Tracing 11C-methionine (for brain tumours) and 11C- and 18F-
holine derivatives (prostate and urological tumours, glioma and
epatocellular carcinoma) are by now in advanced investigational
linical use [23]. Methionine and choline are both involved in
mportant inter-connected pathways of one carbon metabolism,
ncluding THF production and DNA methylation, therefore these
racers allow powerful detection of a range of malignancies.
.1.3. 18Fluoro-thymidine (FLT)
A thymidine analogue, FLT is used to directly detect tumour cell
roliferation, taking advantage of the high DNA replication and cell
ivision rates of many malignant tumours [33]. Following its phos-
horylation by thymidine kinase 1 (TK1), which shows increased
ctivity during the S-phase of the cell cycle, FLT is trapped within
ividing cells, enabling their imaging [23]. Therefore, FLT-PET holds
romise for distinguishing malignancy from inﬂammation and may
lso allow the use of PET diagnostics for less avidly glycolytic can-
ers.
.1.4. 18Fluoro-glutamine
Glutamine – through its conversion to glutamate by glutami-
ases (GLS1 and GLS2) – fuels the tri-carboxylic acid (TCA) cycle,
enerates “reducing power” and contributes to the synthesis of
on-essential amino acids via cytosolic or mitochondrial transami-
ases [34]. 4-18F-(2S,4R)-ﬂuoro-glutamine (18F-FGln), designed to
etect glutamine consumption and utilisation, has been suggested
s a tumour-speciﬁc tracer in both mouse brain tumour models and
lioma patients, and is currently being clinically evaluated in other
alignancies too [35,36].
.1.5. Hyperpolarised 13C metabolic tracers
By dramatically increasing signal-to-noise-ratios, “hyperpolari-
ation” of the nuclear spins of 13C-labelled metabolites has enabled
RS  imaging of these isotopes in vivo [37]. In addition to evaluat-
ng their immediate transport, the metabolic fate of these labelled
ubstrates can be traced in various tissues [38]. This principle has
een applied in different cancer models to assess extracellular
H (using the 13C-bicarbonate to 13CO2 ratio), alterations in gly-
olytic ﬂux (from 13C-glucose to 13C-lactate), production of the
ncometabolite 2HG (from 13C-glutamate), redox stress (via 13C-
ehydroascorbate), and for detecting cancer cells on a background
f healthy mouse liver tissue (reading [1,3-13C2]ethylacetoacetate)lopmental Biology 43 (2015) 52–64 55
[39–42]. Pre-clinical results with MRS  imaging indicated that,
due to its favourable hyperpolarisation characteristics and broad
metabolic utilisation in malignant cells, 13C-pyruvate is a lead can-
didate for tracing cancer metabolism in situ (via its conversion to
13C-lactate by lactate dehydrogenase (LDH)) and a good indicator of
treatment-induced metabolic alterations [43,44]. In line with this,
Nelsen et al. recently reported the ﬁrst clinical study employing
hyperpolarised 13C-pyruvate for tumour imaging. In 31 patients
with localised prostate cancer a higher degree of conversion of
pyruvate to lactate was  conﬁrmed in the carcinomas compared to
tumour-free tissues [45]. Moreover, this method appeared supe-
rior to standard (+H-based) magnetic resonance imaging (MRI) for
identifying the more aggressive carcinomas [45]. New hyperpo-
larised metabolic MRS  imaging tracers are under development and
the prospect of simultaneously hyperpolarising and tracking sev-
eral molecules in vivo highlights molecular metabolic imaging as
one of the most rapidly advancing ﬁelds in cancer diagnostics [46].
3.2. Applied analytical metabolomics in the clinic: from
biomarkers to novel molecular targets
In this section we  highlight the power of analytical metabolomic
investigations in humans. The use of nuclear magnetic resonance
(NMR) or mass spectrometry to provide medium- to high-
throughput metabolic proﬁles, techniques collectively known as
“metabolomics”, is a powerful approach recently incorporated into
the research arsenal in the clinic. Besides the increasing application
of metabolism-based imaging techniques, four main approaches for
investigating cancer-driven metabolic re-programming in humans
exist: First, the comparing of tumour metabolomes to those of adja-
cent normal tissues after resection in sano. Second, the metabolic
tracing in patients of systemically administered stable isotope-
labelled substrates (e.g. 13C-labelled glucose) can provide a more
dynamic metabolic picture. Third, more detailed metabolic trac-
ing can be performed in thin tissue slices derived from freshly
resected tumours ex vivo. Last, body ﬂuids such as blood, urine
and saliva can be easily and repeatedly analysed for their compo-
sition at different stages of malignancy, in response to treatment
or after administration of a labelled metabolite. Together, these
methods may  provide valuable “integrative” insights into tumour
metabolism and dynamics, and enable the discovery of biomark-
ers that quantitatively or qualitatively correlate with malignant
features. Fig. 1 summarises different approaches to investigating
cancer metabolism in patients; a selection of recent studies is dis-
cussed hereinafter.
3.2.1. Mechanistically informative metabolic biomarkers
In a metabolomic proﬁling study of untreated gliomas, 2HG
was identiﬁed to be the major grade-discriminating metabolite
in the low grade tumours [13]. Furthermore, in higher grade
tumours, three metabolically deﬁned subtypes (“anabolic”, “ener-
getic” and “phospholipid catabolic”) were identiﬁed and correlated
with the prognosis of the respective patients. These metabolic
subgroups were largely independent from the gene expression
proﬁle-based tumour stratiﬁcation [13]. Another integrative study,
which metabolically characterised diffuse large B cell lymphoma,
identiﬁed a subset of tumours with increased oxidative energy
metabolism [11]. In both studies, the metabolic proﬁling provided
informative signatures that helped characterise these tumours, and
suggested potential liabilities for future investigation.
Pancreatic cancer remains a rapidly fatal disease for most
patients, partly since it is most often detected at an advanced stage.
Mayers et al. took advantage of a large number of blood samples
acquired over multiple studies, and searched for potential diagnos-
tic biomarkers by identifying early changes in systemic metabolite
concentrations, which associated with the later development of
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Table 1
Current clinical investigations of metabolism-related imaging compounds in cancer medicine.
Tracing Entity Trial number Lead site
FDG-PET Various >250 Open trials Various sites
FLT-PET Various >35 Open trials Various sites
11C-methionine- PET Glioblastoma NCT01867593
NCT01873469
Massachusetts General Hospital, Boston, USA
Technische Universität Dresden, Dresden, Germany
Brain tumours JPRN-UMIN000003386 Tokushima University Hospital, Tokushima, Japan
Brain metastases NCT02433171 Yale University, New Haven, USA
Lung  cancer JPRN-UMIN000005096 Osaka University Graduate School of Medicine, Osaka, Japan
Thyroid carcinoma NTR1937 University Medical Centre Groningen, Groningen, The Netherlands
Various NCT00840047
JPRN-UMIN000016128
JPRN-UMIN000002048
JPRN-UMIN000004043
St. Jude Children’s Research Hospital, Memphis, USA
Hokkaido University Hospital, Sapporo, Japan
Saitama Medical University, Saitama, Japan
Kyoto University Hospital, Kyoto, Japan
18F-FGln-PET Solid malignancies, lymphoma NCT01697930 Memorial Sloan Kettering Cancer Center, New York, USA
11C-acetate-PET Prostate carcinoma NCT01304485
NCT01530269
NCT01777061
Arizona Molecular Imaging Center, Phoenix, USA
Arizona Molecular Imaging Center, Phoenix, USA
University of Kansas Medical Center Research Institute, Fairway, USA
Bladder carcinoma NCT01918592 Turku University Hospital, Åbo, Finland
Glioma NCT01961934 Arizona Molecular Imaging Center, Phoenix, USA
Multiple myeloma NCT01691300 Chang Gung Memorial Hospital, Gueishan, Taiwan
11C-choline-PET Prostate carcinoma NCT02260817
NCT02397408
NCT02232724
NCT02232672
JPRN-UMIN000013377
EUCTR2013-001330-17-IT
Decatur Memorial Hospital, Decatur, USA
University of California, San Francisco, USA
Odense University Hospital, Odense, Denmark
Odense University Hospital, Odense, Denmark
National Centre for Global Health and Medicine, Tokyo, Japan
IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto
Nazionale per la Ricerca sul Cancro, Genoa, Italy
18F-choline-PET Prostate carcinoma NCT01981707
NCT02232685
NCT02397408
NCT01751737
NCT01804231
NCT02131649
EUCTR2009-014839-21-FR
EUCTR2011-004951-38-IT
EUCTR2009-011189-27-IT
EUCTR2008-004236-20-IT
University Hospital, Grenoble, France
Odense University Hospital, Odense, Denmark
University of California, San Francisco, USA
University of Michigan, Ann Arbour, USA
Lawson Health Research Institute, London, Canada
Lawson Health Research Institute, London, Canada
CIS bio international, member of IBA group, France
Programma Ricerca e Innovazione, Forli, Italy
Istituti Fisioterapici Ospitalieri, Roma, Italy
Azienda Ospedaliera Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
HCC  NCT01116804 University Hospital, Ghent, Belgium
Breast cancer NCT01956409 National Taiwan University Hospital, Taipei, Taiwan
Glioma EUCTR2009-011380-37-IT Azienda Ospedaliera Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
18F-methylcholine- PET Prostate carcinoma NCT00928252
EUCTR2013-004397-99-ES
EUCTR2007-004419-69-FR
EUCTR2008-003337-24-IT
Queen’s Medical Center, Honolulu, USA
Instituto Tecnológico PET, S.A.U. (ITP), Madrid, Spain
Assistance publique – Hôpitaux de Paris, Paris, France
IRCCS CROB, Rionero In Vulture PZ, Italy
HCC NCT01395030 Queen’s Medical Center, Honolulu, USA
High grade glioma NCT00628940 University Hospital, Ghent, Belgium
Breast cancer EUCTR2011-003036-31-IT Medicina Nucleare Biomolecolare, Florence, Italy
18F-ethylcholine- PET HCC NCT02238769 Peking Union Medical College Hospital, Beijing, China
Prostate carcinoma EUCTR2012-004297-26-IT
EUCTR2006-003933-33-DE
Ist. Medicina Nucleare, Roma, Italy
Bundeswehr, Germany
Endometrial carcinoma,
cervical carcinoma
NCT01836484 Barts & The London NHS Trust, London, UK
18F-FSPG-PET
(BAY94-9392)
HCC NCT02379377 Vanderbilt-Ingram Cancer Center, Nashville, USA
Brain  cancer NCT02370563 Stanford University Medical Center, Stanford, USA
Lung cancer NCT02448225 Vanderbilt-Ingram Cancer Center, Nashville, USA
FET-PET Glioblastoma NCT02329795
NCT01756352
Rigshospitalet, Copenhagen, Denmark
Brigham and Women’s Hospital, Boston, USA
O-2-FET-PET Low grade glioma NCT02286531 University Hospital, Toulouse, France
2HG  detection (MRS) Glioma NCT02388659 University of Texas Southwestern Medical Center, Dallas, USA
Hyperpolarised
13C-Pyruvate
Malignant solid tumours NCT02421380 Memorial Sloan Kettering Cancer Center, New York, USA
Prostate carcinoma NCT02450201 University of California, San Francisco, USA
Even though Table 1 states the lead site for most trials, many trials are conducted at several sites (sources: www.clinicaltrials.gov [only open clinical trials with reported
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8F-(2S,4R)-ﬂuoroglutamine; FLT, 18F-ﬂuorothymidine; 18F-FSPG, 18F-ﬂuoro-L-gluta
RS,  magnetic resonance spectroscopy; PET, positron emission tomography.
ancreatic ductal adenocarcinoma (PDAC) [47]. Employing tar-
eted metabolic proﬁling, they found that branched-chain amino
cids (BCAAs) were elevated in the plasma of affected individ-
als 2–10 years prior to diagnosis with PDAC [47]. Their ﬁndings
ere afﬁrmed in a mouse model of PDAC, but not in other KRAS-
ssociated cancers, implying tumour-speciﬁc changes in systemic
rotein (amino acid) metabolism at very early stages of this malig-
ancy. Thus a simple blood screening may  detect PDAC at its initialcluded]). FDG, 18F-ﬂuorodeoxyglucose; FET, 18F-ﬂuoroethyltyrosine; 18F-FGln, 4-
 derivative BAY94-9392; HCC, hepatocellular carcinoma; 2HG, 2-hydroxyglutarate;
stage, when complete surgical resection, the only curative option,
is still possible. However, since elevated BCAAs levels were found
to be associated with a twofold increase in PDAC risk and for a
limited window prior to diagnosis only, other prognosticators are
required in order to deﬁne the population that would beneﬁt from
intensiﬁed surveillance [47]. Further studies in PDAC metabolomics
and the integration of results with genetic information, such
as performed by Zhang et al., whose ﬁndings pointed towards
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e-regulated fatty acid metabolism in PDAC [48], are likely to
rovide new insights and pave the way to new therapeutic strate-
ies, urgently needed for this disease.
In another biomarker-driven study of more than 200 acute
yeloid leukaemia (AML) patients, many plasma metabolites were
ound to be elevated in comparison to healthy controls [49]. Here,
 proﬁle of six central metabolites (lactate, -ketoglutarate, pyru-
ate, 2HG, glycerol-3-phosphate and citrate) was sufﬁcient for
rognostic patient stratiﬁcation in cytogenetically normal AML, a
urrently highly heterogeneous subgroup with regards to thera-
eutic outcome. Model-based investigation further implied that
igh glycolytic activity could be associated with resistance to
ytarabine, a drug commonly used to treat AML, and that phar-
acologically interfering with glycolysis may  increase the efﬁcacy
f cytarabine treatment in AML  patients [49].
.2.2. Metabolomics-driven target identiﬁcation: pyruvate
arboxylase activity in lung cancer
Combining in vivo and ex vivo approaches, the group of Theresa
an studied non-small cell lung cancer (NSCLC) specimens from
ver 80 patients, analysing metabolic adaptations [12,50]. They
njected patients with uniformly 13C-labelled glucose and, after
esection, analysed its intra-tumoural metabolic fate. They found
hat tumours had a speciﬁc increased activity of pyruvate carboxy-
ase (PC). PC is an anaplerotic enzyme that carboxylates pyruvate
irectly to oxaloacetate; hence its activity sustains TCA cycle
etabolite levels. Ex vivo experiments comparing the metabolite
abelling patterns of malignant and non-cancerous tissue slices
rom the same patients conﬁrmed the in vivo results. In line
ith this, genetic PC silencing in different NSCLC models exerted
rowth-inhibitory effects [12].
. Genetic biomarkers for future diagnosis, novel
herapeutic strategies and patient stratiﬁcation
Direct deduction of a genetic status of a tumour from its
etabolic proﬁle remains an improbable goal. However, genetic
creening for changes in gene expression, promoter methylations
r the copy number of “metabolic genes” may  constitute a better
trategy for arriving at a prognosis or for speciﬁc treatment allo-
ation than metabolomics data. Examples of the most promising
linically relevant alterations in metabolic genes are given below.
.1. IDH oncogenic mutations
The IDH enzyme exists as three distinct isoforms: IDH1 (cyto-
ol and peroxisomes), IDH2 (mitochondria), IDH3 (mitochondria
 TCA cycle), and normally catalyses the oxidative decarboxyl-
tion of isocitrate to -ketoglutarate. To date IDH3 mutations
n cancer have not been detected, whereas point mutations in
he catalytic sites of both IDH1 and IDH2 are found in glioma,
ML and several other cancers [51–56]. These mutations result
n a new, pathological, catalytic activity namely the reduction of
-ketoglutarate to 2HG. By the competitive inhibition of demethy-
ases (of the -ketoglutarate-dependent dioxygenase family), 2HG
lters the epigenome [57,58]. IDH-mutated tumours provide a rare
pportunity to speciﬁcally target a “metabolic oncogene” with-
ut interfering with normal metabolism, and clinical trials in
ML and glioma are currently testing small-compounds inhibitors
f IDH (AG-120 against IDH1 or AG-221 against IDH2), or vac-
ine immunotherapy against IDH1 neoantigen [59] (Table 2). In
ddition, other IDH inhibitors as well as other IDH-mutated malig-
ancies are being investigated (Table 2). It is noteworthy that in
ower grade glioma, IDH1/2 gain of function mutations confer a
elatively favourable prognosis [60,61], whereas data are much less
lear for AML  [62,63]. The mutational status of IDH1 and IDH2 andlopmental Biology 43 (2015) 52–64 57
the degree of 2HG production are likely to be incorporated into
routine diagnostic algorithms for glioma and AML [64,65].
4.2. SDH and FH loss-of-function mutations
Two  other metabolic enzymes, FH and SDH, are mutated in
some rare cancers and loss of their enzymatic activity provokes
the accumulation of fumarate and succinate, respectively. These
metabolites inhibit a plethora of dioxygenases and so act as
oncometabolites (recently reviewed in [66]). Typically, inactiva-
tion of either of the metabolic tumour suppressors SDH and FH
occurs by loss of heterozygosity in patients with a familial pre-
disposition to cancer due to a mono-allelic germline mutation in
one of these genes [67]. Families at risk are relatively easily iden-
tiﬁed and screened regularly. The detection of germline mutations
in FH and SDH guides patient management, and therefore they can
be considered as clinical biomarkers. Renal cell carcinomas (RCC),
due to either mutation, are aggressive and metastatic [68] and they
are accepted (FH) or provisionally considered (SDH) to comprise
distinct tumour subtypes in a current RCC classiﬁcation [69,70].
SDH inactivation also occurs in a fraction of gastrointestinal stro-
mal  tumours (GIST) without c-kit mutations [71,72]. Hence, the use
of c-kit directed tyrosine kinase inhibitors, a therapeutic standard
in advanced GIST, may  be ineffective in SDH-deﬁcient cases. SDH
inactivation is increasingly observed in other malignancies [73–75]
and may  acquire diagnostic relevance once compounds that inter-
fere with the resulting epigenetic [76] or metabolic [77] rewiring
become available.
A recent work has uncovered an essential role of PC in SDH-
deﬁcient tumours [77]. Using metabolic proﬁling of primary human
phaeochromocytoma and paraganglioma, Cardaci et al. found sig-
niﬁcantly decreased aspartate levels in SDH-mutated cases when
compared to SDH-proﬁcient neoplasms. Loss of SDH activity and
therefore TCA cycle truncation, results in a decrease of oxaloacetate
synthesis, and consequently, lower aspartate levels. The increased
PC activity compensates for and bypasses the TCA cycle block and
partially sustains aspartate synthesis. Elevated PC protein expres-
sion was  also detected in SDH-mutated RCC specimens when
compared to same-patient adjacent non-cancerous kidney tissues.
Moreover, genetic silencing of PC limited the proliferation and
tumorigenic capacity of SDH-mutated cells. Therefore, it is now
tempting to speculate that pharmacological targeting of PC may
offer an effective therapeutic strategy for SDH-deﬁcient tumours
(and NSCLC – see above).
4.3. Argininosuccinate synthetase 1 (ASS1) deﬁciency
ASS1 is a urea cycle enzyme which catalyses one of the key
steps of arginine biosynthesis in mammals. Genetic or epige-
netic silencing of ASS1 in various solid tumours and AML  renders
them auxotrophic of this otherwise non-essential amino acid
[7,78–80]. Mechanistically, lack of ASS1 activity supports prolif-
eration because aspartate, one of its substrates, is then free for
use in nucleotide biosynthesis [81]. Therapeutically, since ASS1
loss induces arginine auxotrophy, depleting plasma arginine using
systemic administration of bacterial or bio-engineered arginase or
arginine deiminases (ADI), is being tested in clinical trials, showing
efﬁcacy in these tumours ([79,82,83], Table 2).
4.4. Acetyl-CoA synthetase 2 (ACSS2) induction
The metabolic role of acetate in cancer was outlined in Section
3.1.1. Recently, acetate metabolism in cancer was  revisited with
a fresh look. By applying in situ tumour metabolomics directly in
patients, Maher et al., provided evidence for high TCA cycle activity
in glioblastomas [84]. Following intravenous infusion of uniformly
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Table 2
Current clinical investigation of metabolism-related compounds as cancer treatment.
Target  Compound  Entity  Trial  number  Lead  site
MCT1  AZD3965  Advanced  solid  tumour,
prostate  carcinoma,  gastric
cancer,  DLBCL
NCT01791595  Royal  Marsden  Hospital,  London,  UK
Polyamines DMFO Neuroblastoma  NCT02030964
NCT02395666
NCT02139397
Children’s  Hospital  Los  Angeles,  Los  Angeles,  USA
Helen DeVos  Children’s  Hospital,  Grand  Rapids,  USA
Helen DeVos  Children’s  Hospital,  Grand  Rapids,  USA
(Prevention of) CRC  NCT00983580
NCT01483144
NCT01349881
Mayo  Clinic,  Rochester,  United  States
Multinational
689 sites,  USA
Arginine (plasma)  Pegylated  arginase
(BCT-100)
HCC NCT02089763
NCT02089633
NCT02285101
Prince  of  Wales  Hospital,  Hong  Kong,  China
Queen Mary  Hospital,  Hong  Kong,  China
Loma Linda  University  Medical  Center,  Loma  Linda,  USA
RCC, melanoma,  prostate
carcinoma
NCT02285101  Loma  Linda  University  Medical  Center,  Loma  Linda,  USA
Pegylated arginine
deiminase
(ADI-PEG 20)
Advanced  solid  tumours  NCT01497925
NCT01665183
University  of California  at  Davis  Sacramento,  USA
MD Anderson  Cancer  Center,  Houston,  USA
(gastrointestinal) NCT02102022  Memorial  Sloan-Kettering  Cancer  Center,  New  York,  USA
Melanoma NCT01665183
NCT02029690
MD  Anderson  Cancer  Center,  Houston,  USA
Centre  for  Experimental  Cancer  Medicine  (CECM),  London,  UK
Mesothelioma NCT02029690
EUCTR2006-004592-35-GB
Centre  for  Experimental  Cancer  Medicine  (CECM),  London,  UK
Centre for  Experimental  Cancer  Medicine  (CECM),  London,  UK
NSCLC NCT02029690  Centre  for  Experimental  Cancer  Medicine  (CECM),  London,  UK
Glioma NCT02029690  Centre  for  Experimental  Cancer  Medicine  (CECM),  London,  UK
HCC NCT02029690
NCT02101593
NCT02006030
EUCTR2011-002041-36-GB
Centre  for  Experimental  Cancer  Medicine  (CECM),  London,  UK
MD Anderson  Cancer  Center,  Houston,  USA
National  Taiwan  University  Hospital,  Taipei,  Taiwan
Multinational
Breast cancer  NCT01948843  MD  Anderson  Cancer  Center,  Houston,  USA
Pancreatic carcinoma NCT02101580  Memorial  Sloan-Kettering  Cancer  Center,  New  York,  USA
NHL NCT01910025  Chang  Gung  Medical  Foundation-Kaohsiung,  Kaohsiung,  Taiwan
AML NCT01910012  MD  Anderson  Cancer  Center,  Houston,  USA
Glutamine (plasma)  (PEG-)  asparaginase  AML,  ALL,  NHL,  pancreatic
carcinoma
>50  Open  trials  Various  sites
Glutaminase CB-839 AML, ALL  NCT02071927  Various  sites,  USA
Multiple myeloma,  NHL  NCT02071888  Various  sites,  USA
Solid malignancies  (including
FH-,  SDH-deﬁcient  and
IDHmt  tumours)
NCT02071862  Various  sites,  USA
mt. IDH1 AG-120 IDH1mt  AML/haematological
malignancies
NCT02074839  Various  sites,  USA  and  France
IDH1 mt  solid  malignancies  NCT02073994  Various  sites,  USA  and  France
IDH305 IDHR132  mt  advanced
malignancies
NCT02381886  Multinational
Peptide vaccine IDH1mt  glioma  grade  III–IV  NCT02454634  National  Centre  for Tumour  Diseases,  Heidelberg,  Germany
IDH1mt Glioma  grade  II NCT02193347  Duke  Comprehensive  Cancer  Center,  Durham,  USA
mt. IDH2 AG-221 IDH2mt  haematological
malignancies
NCT01915498  Various  sites,  USA  and  France
IDH2mt solid  malignancies  NCT02273739  Various  sites,  USA  and  France
IDH2mt AILD  NCT02273739  Various  sites,  USA  and  France
mt. IDH1/2 AG-881 IDH1/2mt  haematological
malignancies
NCT02492737  MD  Anderson  Cancer  Center,  Houston,  USA
IDH1/2mt solid  tumours  NCT02481154  Various  sites,  USA
Glutathione Dimethylfumarate Glioblastoma NCT02337426  Virginia  Commonwealth  University,  Richmond,  USA
Cutaneous T-NHL  EUCTR2014-000924-11-DE  University  Medical  Centre  Mannheim,  Mannheim,  Germany
mTOR, complex  1 Metformin  Various  >100  Open  trials  Various  sites
Cholesterol synthesis  Statins  Various  >20  Open  trials  Various  sites
General tumour
metabolism
Modiﬁed  diets  Various  >400  Studies  Various  sites
Ketogenic diets Glioblastoma  NCT02286167
NCT02302235
NCT02046187
NCT01535911
NCT01754350
NTR5167
Mid-Atlantic  Epilepsy  and  Sleep  Center,  Bethesda,  USA
Mid-Atlantic  Epilepsy  and  Sleep  Center,  Bethesda,  USA
St. Joseph’s  Hospital  and  Medical  Center,  Phoenix,  USA
Michigan State  University/Sparrow  Hospital,  E. Lansing,  USA
Johann Wolfgang  Goethe  University  Hospital,  Frankfurt,  Germany
Erasmus Medical  Centre,  Rotterdam,  The  Netherlands
Rectum carcinoma  NCT02516501  Leopoldina  Krankenhaus,  Schweinfurt,  Germany
Breast carcinoma  NCT02516501
NCT02092753
Leopoldina  Krankenhaus,  Schweinfurt,  Germany
Rehaklinik  Am  Kurpark,  Bad  Kissingen,  Germany
Head and  neck  cancer  NCT02516501
NCT01975766
Leopoldina  Krankenhaus,  Schweinfurt,  Germany
Holden  Comprehensive  Cancer  Center,  Iowa City,  USA
“Atkins diet” Glioblastoma  NCT02286167  The  Johns  Hopkins  Hospital,  Baltimore,  USA
Prostate carcinoma  NCT00932672  Duke  University  Medical  Center,  Durham,  USA
Fasting Various  >150  Trials  Various  sites
Even though Table 2 states the main site for most trials, many trials are conducted at several sites (sources: www.clinicaltrials.gov [only open clinical trials with reported
status  were included] and http://apps.who.int/trialsearch [only recruiting trials were included]). ADI, arginine deiminase; AILD, angioimmunoblastic T-cell lymphoma;
AML,  acute myeloid leukaemia, ALL, acute lymphoblastic leukaemia; CRC, colorectal cancer, DMFO, diﬂuoromethylornithine, FH, fumarate hydratase; HCC, hepatocellular
carcinoma; MDS, myelodysplastic syndrome; MCT, monocarboxylate transporter; mt,  mutated; mTOR, mammalian Target of Rapamycin; NHL, non-Hodgkin’s lymphoma;
PEG,  polyethyleneglycol; RCC, renal cell carcinoma, SDH, succinate dehydrogenase.
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abelled 13C-glucose, MRS  imaging of intra-tumoural metabolites
ndicated a source, in addition to glucose, of acetyl-CoA [84]. In
 follow-up study, Mashimo and colleagues identiﬁed acetate as
 “bioenergetic substrate” for glioblastoma and brain metastases
y tracing the intracellular fate of 13C-labelled acetate, following
ts administration to patients during surgery [30]. Together with
ecent work by Schug et al. [31] and Comerford et al. [85], these ﬁnd-
ngs point at the acetate metabolising enzyme, ACSS2, as a potential
herapeutic target.
ACSS2 converts acetate into its metabolically active form acetyl-
oA. Gain in copy number of the ACSS2 locus in breast cancer
as recently reported, with signiﬁcantly higher ACSS2 mRNA and
rotein level associated with poorer prognosis [31]. These results
ccord with other studies in triple-negative breast cancer, primary
uman ovarian and lung tumours, metastatic prostate carcino-
as  and glioma patients [30,31,85]. Furthermore, patient-derived
odels of glioma and brain metastases of other cancers revealed
hat ACSS2 upregulation causes preferential metabolic utilisation
f acetate by malignant tumours in the central nervous system
30]. These ﬁndings suggest that ACSS2 expression levels may  help
dentify high-risk patients.
.5. Addiction to the serine and glycine biosynthetic pathway
D-3-phosphoglycerate dehydrogenase (PHGDH) catalyses the
ate limiting step of serine biosynthesis, converting the gly-
olytic intermediate 3-phosphoglycerate to 3-phospho-hydroxy-
yruvate, and has been found to be genetically ampliﬁed,
verexpressed or otherwise essential for the growth of melanoma,
s well as colorectal and breast cancer [5,8,86]. The mitochondrial
nzyme serine hydroxyl-methyl-transferase 2 (SHMT2) converts
erine to glycine, thereby freeing one carbon unit that supports THF
nd nucleotide biosynthesis. Publically available gene expression
ata sets revealed shmt2 copy-number gain and overexpression in
reast and ovarian cancer and in NSCLC and melanoma [87,88]. Ele-
ated SHMT2 expression has also been linked to an adverse patient
utcome in neuroblastoma, NSCLC and breast cancer [87–89]. Co-
xpression of SHMT2 and glycine decarboxylase (GLDC), which
revents the toxic accumulation of glycine in SHMT2 express-
ng cells, was  speciﬁcally detected in hypoxic regions of gliomas,
hereby providing them with a metabolic advantage under hypoxia
90]. PHGDH, SHMT2 and GLDC may  not only serve as prognostic
arkers, but, in the future, serine/glycine metabolism may  be the-
apeutically targeted (e.g. patent applications US 2014/0087970 A1
nd US20150011611 A1).
. Developing therapeutic metabolic modalities in the
linic
Beyond the few approved tools in the clinic (Section 2), cumu-
ative understanding of metabolic transformation has led to the
evelopment, repositioning or reassessment of metabolic-speciﬁc
rugs and therapeutic approaches (Table 2).
.1. Searching for direct interference with metabolic pathways
Here we describe drugs speciﬁcally designed to interfere with
umour metabolism that are either being currently assessed (or re-
valuated) in clinical trials (Table 2) or, to our knowledge, are in
dvanced stages of pharmacological and pre-clinical development..1.1. 2-Deoxyglucose (2DG)
In the 1950s, 2DG, a glucose analogue that enters, but is not
etabolised by cells was  designed to target glycolytic tumour cells
y competing with glucose [91]. Once phosphorylated by the ﬁrstlopmental Biology 43 (2015) 52–64 59
glycolytic enzyme, hexokinase, the accumulated 2DG-6-phosphate
inhibits glycolysis [92], causes growth arrest and apoptosis and
thereby potentiates the activity of classical antineoplastic agents
[93,94]. Unfortunately, clinical studies revealed limiting systemic
toxicity of 2DG leading to use of lower (and therefore less efﬁcient)
doses [95]. More recently, combinations of 2DG  with chemothera-
peutic drugs were tested in solid tumours (e.g. trial NCT00096707),
but we are not aware of currently recruiting trials. Lonidamine,
another glycolytic inhibitor, has also been evaluated in clinical tri-
als, but like 2DG, has failed to provide a therapeutic beneﬁt to date
[96].
5.1.2. Nicotinamide phosphoribosyltransferase (NAMPT)
Nicotinamide adenine dinucleotide (NAD) is a central coen-
zyme required for many reactions of cellular metabolism and
redox balance. In cancer cells NAD is mostly regenerated from
nicotinamide-mononucleotide. Nampt encodes the rate-limiting
enzyme of the NAD salvage pathway, and its increased gene expres-
sion has been observed in a variety of cancer entities ([97,98],
reviewed in [99]). NAMPT activity increases the abundance of
NAD+, also a coenzyme of the deacetylase silent information regula-
tor 1 (SIRT1), thereby activating the oncogene c-myc and inhibiting
the senescence and apoptosis responses to oncogenic activation
[100]. Moreover, NAMPT is actually transcriptionally activated by c-
MYC  [100]. Corroborating the vulnerability of tumour cells to NAD+
depletion, a speciﬁc, non-competitive inhibitor of NAMPT, FK866,
was shown to induce apoptosis in a variety of tumour cell lines
[101]. The high NAD+ demand of the DNA repair and apoptosis regu-
lator Poly [ADP-ribose] polymerase 1 (PARP1) may  partially explain
the selective toxicity that NAMPT inhibitors inﬂict on cancer cells
and suggests combining NAMPT inhibition with DNA-damaging
agents as therapeutic strategies [101–103]. Moreover, high nampt
gene expression has been linked to resistance to the proteasome-
inhibitor bortezomib, and to poorer outcome in relapsed multiple
myeloma [104]. Accordingly, pre-clinical treatment with FK866, as
well as its combination with bortezomib, has indicated beneﬁcial
effects in this disease [105]. An alternative way to re-generate NAD+
in malignant cells (potentially generating resistance to NAMPT
inhibition) relies on the enzyme nicotinic acid phosphoribosyl-
transferase (NAPRT) [99]. Therefore, NAPRT-deﬁcient tumours such
as a substantial fraction of glioblastomas, neuroblastomas and sar-
comas may  be particularly sensitive to NAMPT inhibition [106].
Despite the convincing biological rationale for the use of NAMPT
inhibitors depicted above, early clinical trials for advanced solid
malignancies revealed substantial side effects (mainly haematolog-
ical and gastrointestinal) and suggested only modest anti-tumour
efﬁcacy when the drugs were used as single agents [107–109].
The development of more potent NAMPT inhibitors, a more thor-
ough patient stratiﬁcation strategy, drug administration earlier in
the course of disease and identiﬁcation of promising therapeutic
combinations may  provide better prospects for the use of NAMPT-
targeting drugs.
5.1.3. Polyamines and arginine biosynthetic pathways
Despite being involved in virtually all cellular functions,
polyamines (a class comprising three molecules produced succes-
sively from arginine and ornithine: putrescine, spermidine and
spermine, and their acetylated derivates) are interesting targets for
cancer-directed therapies due to their important role in cell prolif-
eration speciﬁcally [110]. Several inhibitors of enzymes involved
in polyamine synthesis, such as diﬂuoromethylornithine (DFMO),
were developed and tested in clinical trials either as chemopre-
ventives or chemotherapeutics [111] (Table 2). Arginine itself can
be converted to ornithine but, in addition to being a polyamine
precursor, arginine seems to have other important roles in some
cancers [80]. Arginine metabolism is highly connected the urea
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ycle too and provides cancer cells with a way of disposing of nitro-
en residues. Ornithine is a central intermediate at the “crossroad”
f proline, urea and polyamine pathways. As discussed in Section
.3, arginine-depleting approaches in ASS1-silenced tumours are
emonstrating efﬁcacy.
.1.4. Glutaminase (GLS)
The idea of interrupting the supply or utilisation of the
onditionally-essential amino acid glutamine in order to ﬁght
ancer dates back several decades and is based on its high con-
entration in plasma as well as the selective vulnerability of
 variety of malignant cells to glutamine depletion [3,112,113].
nterestingly, the antineoplastic effects of asparaginase (discussed
n Section 2.3) have been partly linked to its additional, inher-
nt glutamine-depleting function [114]. Intracellular glutaminases
atalyse the deamination of glutamine to glutamate, which can
erve as a precursor for -ketoglutarate (for anaplerosis) or for
lutathione (antioxidant) [113,115]. Of the two human glutam-
nase genes, gls2 expression is mainly restricted to the liver,
hereas the product of gls1 (kidney-type GLS) can be found in
ost tissues [116]. In line with a pivotal role in metabolic rewiring
uring tumorigenesis, GLSs are differentially regulated by tumour
uppressors and oncogenes [117,118]. GLS inhibitors such as bis-
-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulﬁde (BPTES)
ave shown therapeutic activity in tumour models with elevated
LS activity without prohibitive systemic toxicity [4,119,120].
dditionally, metabolic proﬁling of IDH1/2-mutated glioma cells
as shown a decrease in -ketoglutarate abundance and, conse-
uently, GLS inhibition exhibited selective toxicity in these gliomas
121,122]. Currently, clinical phase I trials with the orally available
nhibitor of GLS1, CB-839 [123], are being conducted in both solid
nd haematological malignancies, but, to the best of our knowledge,
esults have not yet been reported in peer-reviewed publications.
.1.5. Lactate metabolism
Due to increased aerobic glycolysis in many malignancies, pyru-
ate is largely transformed into lactate by LDH and exported to
he micro-environment by monocarboxylate transporters (MCTs).
he A subunit of LDH favours the reduction of pyruvate to lac-
ate in conjunction with oxidising cytosolic NADH to NAD+ hence
upporting high glycolytic ﬂux. LDHA is a direct target of the
ypoxia inducible transcription factors (HIFs) and of several acti-
ated oncogenes, and consequently is overexpressed in a variety
f malignancies [124]. Silencing LDHA in hypoxic breast can-
er models decreased tumorigenicity [125]. Additionally, genetic
r pharmacologic LDHA inhibition elevated mitochondrial reac-
ive oxygen species, induced cell death [126–128] and selectively
mpaired the growth of patient-derived xenografts [129]. In a
odel of NSCLC, LDHA inhibition was toxic to tumour-initiating
ells, and primary human NSCLC tissue slices ex vivo showed a
ecrease in the conversion of 13C-labelled glucose to lactate as
ell as in anaplerotic glutamine consumption [127]. Furthermore,
ollowing anti-angiogenic treatment, in vivo metabolic tracing of
3C-glucose in patient-derived glioblastoma xenografts revealed
ncreased lactate production (a switch to anaerobic metabolism),
nd immunohistochemical analyses of human glioblastoma biop-
ies conﬁrmed higher expression of LDHA [130]. Therefore, LDHA
nhibition may  help neutralising a tumour escape mechanism from
reatment with bevacizumab, an anti-vascular endothelial growth
actor (VEGF) antibody. Several small molecule inhibitors of LDHA
ave been reported over recent years, and some are in advanced
tage of pharmacological development (e.g. [131]). Nevertheless,
o our knowledge, none of these drugs is currently under clinical
valuation.
Once produced by LDH in glycolytic tumours, lactate must be
ecreted from cells via MCTs. High levels of MCT1 are expressedlopmental Biology 43 (2015) 52–64
in various cancer types and MCT4 expression is induced under
hypoxic conditions, typically observed in solid tumours [132].
Therefore, MCTs represent interesting therapeutic targets, with the
MCT1 inhibitor, AZD3965, now being tested against advanced can-
cers in the UK (Table 2) [133]. Unfortunately, MCT1 inhibitors fail
to block MCT4 [134,135] and thus, MCT4 expression, particularly
under hypoxia, overcomes MCT1 inhibition [134,136]. Further-
more, high MCT4 expression is associated with a poor prognosis
in many solid tumours [137–141]. Genetic interference with MCT4
or its chaperone CD147 was effective in different cancer models
[137,138,142] and recently, a speciﬁc MCT4 inhibitor (AZ93) was
reported [133]. Data from pre-clinical studies are eagerly awaited.
5.2. Repositioning non-cancer drugs to anti-cancer strategies
Some drugs, which are already in use for other medical condi-
tions, could potentially serve as effective anti-cancer agents and are
being assessed in clinical trials (Table 2).
5.2.1. Metformin
Metformin, an anti-diabetic drug, modulates both peripheral
insulin-resistance and hepatic gluconeogenesis. It does so by indi-
rectly activating AMP-activated protein kinase (AMPK) through
inhibition of the mitochondrial respiratory chain, thus increasing
the AMP/ATP ratio in cells. Activated AMPK inhibits energy-
demanding anabolic processes and stimulate energy-generating
catabolic processes. It does so partly via the inhibition of mam-
malian Target of Rapamycin (mTOR) which is involved in regulation
of cell proliferation [143]. Metformin is the subject of many ongo-
ing clinical trials with non-diabetic cancer patients (reviewed in
[144]). Disappointingly however, a recent large randomised trial in
advanced pancreatic cancer showed no beneﬁt [145].
5.2.2. Statins
Statins, which are 3-hydroxy-3-methylgutaryl-CoA reductase
inhibitors, target a key enzyme in the mevalonate synthetic path-
way (necessary for cholesterol synthesis). They are conventionally
used to decrease blood cholesterol (reviewed in [146]). As cellular
membranes require cholesterol for stability [147], it was  sup-
posed that impeding cholesterol synthesis would affect tumour cell
growth. Studies aiming at correlating tumour incidence or treat-
ment outcomes to statin use were conducted for various cancers
[148–150], but outcomes have remained largely inconclusive to
date.
5.3. Addressing cancers with modiﬁed diets
Tumour cells compete with normal cells for energy and biomass
supplies. Therefore, limiting nutrient delivery to malignant tissues
may  be a potential therapeutic strategy, and controlling a patient’s
nutrition may  help achieve this goal. Reports suggest that some
tumours lack the ability to use ketone bodies (mainly aceto-acetate
and -hydroxy-butyrate) or fatty acids as energy sources, with the
latter even being toxic to some malignant cells [151–153]. Hence,
ketogenic diets (KD) were investigated with regards to their effects
on cancer progression. Successfully employed to decrease the like-
lihood of seizures in epilepsy patients since the early 1920s (e.g.
[154]), the ﬁrst case-report showing a beneﬁcial effect of KDs on
two girls suffering from astrocytoma was  published in 1995 [155].
Since then, KDs have demonstrated anti-tumour activity in can-
cer cells in vitro [152,156] and in xenografts [151,157], and have
been tested in pilot studies on patients with advanced cancers
[158,159]. Nevertheless, large clinical studies are required to sub-
stantiate these introductory reports and to appreciate who  may
beneﬁt from such an approach.
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. Future perspectives for metabolomics in cancer
iagnosis and therapy
We  herein provide an overview of current and possible future
linical applications of recent advances in metabolomics. Analyt-
cal metabolomics have by now added to our understanding of
ancer pathogenesis. Some metabolic biomarkers are already rou-
inely employed to diagnose malignant diseases and metabolic
lterations of tumours are increasingly being validated as thera-
eutic targets. The importance of altered glucose and glutamine
etabolism in different cancers is well documented. The study
f the metabolic role of non-essential amino acids in malignant
umours is gaining momentum [5–8,160]. New metabolic trac-
rs which may  improve diagnostic accuracy and monitoring of
umours by functional imaging are at different stages of develop-
ent [161], and strategies combining established therapies with
ew metabolism-related approaches are being tested. Further stud-
es in computerised modelling of metabolic networks, pre-clinical
odels, and in primary human tumours, are likely to identify new
etabolic vulnerabilities [162]. However, due to impediments such
s poor speciﬁcity of tool compounds, the presence of compen-
atory metabolic pathways, unforeseen side effects and imprecise
atient stratiﬁcation, several seemingly promising metabolism-
uided strategies have only yielded modest results so far.
The concept of “precision medicine” in cancer care is gradu-
lly gaining structure and strength. In the future, in-depth analyses
f genomic, proteomic and metabolic alterations of an individual
alignant disease, as well as prospective assessment of therapeu-
ic options in mice bearing patient-derived tumour xenografts,
re likely to guide clinical strategies. In addition, personalised
edicine strongly emphasises the use of predictive biomarkers and
ill thereby facilitate the integration of metabolomics into clinical
atient management. Besides discovering and validating metabolic
iomarkers that will enable better diagnosis and monitoring, we
xpect new metabolomics studies to provide new molecular targets
nd enable tailoring of treatments to patients. Relatively inexpen-
ive and reproducible metabolomics analyses, combined with other
omics” approaches, may  soon shape modern medicine. So, despite
bvious obstacles, the increasing use of metabolomics in clinical
esearch may  soon turn it into one of the most powerful tools used
o identify, monitor and ﬁght cancer.
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